David Palma, MD, PhD, of the London Health Sciences Centre, discusses study findings on improvement in survival following stereotactic ablative radiation for oligometastatic tumors (Presentation 5 in PL 01).
Michael Soike, MD, of Wake Forest University Medical Center, discusses results from a large multicenter study that suggests salvage stereotactic radiosurgery leads to improved overall survival compared with whole-brain radiotherapy for patients with progressive brain metastases (Presentation 296 in Scientific Symposium 40).
Alan Pollack, MD, of the University of Miami, discusses study findings on short-term androgen-deprivation therapy with or without pelvic lymph node treatment added to prostate bed–only salvage radiotherapy (Abstract LBA5).
Vinai Gondi, MD, of Northwestern Medicine, discusses the early results of a phase III NRG Oncology trial that suggests a practice change in treating brain metastases: avoiding the hippocampus when delivering whole-brain radiotherapy (Abstract LBA9).
Thomas Galloway, MD, of Fox Chase Cancer Center, summarizes a session on head and neck cancer that included findings on reducing oral mucositis, improving quality of life with deintensified chemoradiotherapy, and the costs of dose de-escalation (Scientific Session 31).
Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall survival compared with maintenance therapy and observation in oligometastatic non–small cell lung cancer (Abstract LBA3).
